View Older Stories View More Recent Stories
-
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Amgen (AMGN) PT Lowered to $320 at RBC Capital; 'Sound Execution Though Safer Pipeline Play'
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Amgen (AMGN) PT Lowered to $324 at RBC Capital Despite Improved Growth Visibility
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
Amgen (AMGN) PT Raised to $362 at RBC Capital
-
2Q24 U.S. biotech earnings preview
-
Amgen (AMGN) PT Raised to $332 at RBC Capital
-
Amgen (AMGN) PT Lowered to $328 at RBC Capital
-
RBC Capital upgrades Amgen (AMGN) on 'improving position of stability' and diminishing uncertainty
-
RBC Capital Upgrades Amgen (AMGN) to Outperform; 'Diversification, Pipeline Optionality & 2024 Catalysts'
-
Amgen completes $27.8 billion Horizon Therapeutics deal
-
Amgen's (AMGN) Inflammation Portfolio Could Become an Important Growth Driver - RBC Capital
-
Amgen's (AMGN) ASCO Updates Overshadowed by LUMAKRAS - RBC Capital
-
Amgen 2020 outlook falls short of Street estimates; shares slump
-
Amgen (AMGN) Lower as Analyst Sees a 'Miss'
-
Amgen's (AMGN) AMG 510 Achieves an ~8% ORR in CRC - RBC Capital
-
Amgen (AMGn) PT Raised to $206 at RBC Capital
-
Amgen (AMGN) PT Raised to $192 at RBC Capital on Increased Enbrel Sales
-
Amgen (AMGN) PT Raised to $192 at RBC Capital
-
Amgen (AMGN) PT Lowered to $189 at RBC Capital
-
Amgen (AMGN) Could See $13 Benefit From NVS Breach - RBC
-
Amgen (AMGN) PT Lowered to $182 at RBC Capital
-
Amgen's (AMGN) Aimovig Sees Hot Script Growth - RBC
-
Amgen (AMGN) PT Lowered to $183 at RBC Capital Following Biosimilar Approval
-
Amgen (AMGN) PT Raised to $184 at RBC Capital
-
Amgen (AMGN) PT Lowered to $183 at RBC Capital
-
RBC Capital Starts Amgen (AMGN) at Sector Perform
-
Trump's corporate tax holiday could spur pharma M&A
-
Notable Analyst Rating Changes 11/8: (CTL) (ETE) (MRC) Upgraded; (CXRX) (HTZ) (IQNT) Downgraded
-
Pfizer cholesterol drug fizzles, hitting shares
-
Amgen (AMGN) Patent Wins Increase Likelihood of Settlement, Says RBC
-
Notable Analyst Rating Changes 12/15: (V) (AMGN) (COH) Upgraded; (BTU) (GOGL) (WSTC) Downgraded
-
Buyers Seem Like Deer-in-Headlights: RBC Capital; Analyst Comments on Biotech Rout
-
RBC Capital Affirms Amgen (AMGN) at 'Outperform'; Repatha Approval Similar to Praluent (REGN) (SNY)
-
Amgen (AMGN) Buy Retained at RBC as Neulasta Biosimilar May Not Come Until Next Year at Earliest
-
Amgen's (AMGN) 'On-Body' IMS Sales Starting to Pick Up - RBC Capital
-
Amgen (AMGN) T-Vec Expectations Low; RBC Comments Following FDA Briefing Docs
-
RBC Comments on Amgen (AMGN) Repatha Data
-
Notable Analyst Rating Changes 10/29: (AMGN) (ALR) (ABT) Upgraded; (PBR) (KORS) (DTE) Downgraded
-
Amgen (AMGN) Suit No Surprise for Regeneron (REGN) - Analyst (SNY)
-
RBC Capital Comments on Biotechs' Irish Tax Strategies; Gilead May See Modest EPS Impact (GILD) (AMGN)
-
Amgen (AMGN) Price Target Raised to $150 at RBC; Breakup Unlikely, Says Analyst
-
Streetinsider.com's Hot Lunchtime Reads 11/26: (MBI) (NOK) (AMGN) (MMR) (AAPL)
-
Notable Analyst Rating Changes 10/22: (BBT) (BEAM) (AMGN) Upgraded; (SNDK) (DDR) (TLM) Downgraded
-
Notable Analyst Rating Changes 07/25: (DOLE) (AMGN) (WHR) Upgraded; (AAPL) (TNK) (PM) Downgraded
-
Human Genome (HGSI) Could Become Takeover Target Upon Approval of Benlysta
-
Notable Analyst Rating Changes 09/14: HOLX, MRX, TOT Upgraded; CPB, XOM, NWL, IPXL Downgraded
